

July 12, 2023

The Manager, Listing Department
The National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051
NSE Symbol : PANACEABIO

BSE Limited
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001
BSE Scrip Code: 531349

Sub: Quarterly report of Investor Complaints under Regulation 13 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the quarter ended June 30, 2023

Dear Sir,

Pursuant to Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, quarterly report towards Investor Grievance for the quarter ended June 30, 2023 is as under:-

No. of Complaints pending at the beginning of the quarter	No. of Complaints received during the quarter	No. of Complaints disposed of during the quarter	No. of Complaints remaining unresolved at the end of the quarter
NIL	NIL	NIL	NIL

A copy of the certificate obtained from the Company's RTA viz. Skyline Financial Services Pvt. Ltd., showing nil complaint during the quarter ended June 30, 2023 is enclosed as Annexure herewith.


This is for your kind information and record please.

Thanking you,

Sincerely yours,
For **Panacea Biotec Ltd.**



 **Vinod Goel**
Group CFO and Head Legal
& Company Secretary



Encl.: As above

B1 Extn. /G3, Mohan Co-op Indl. Estate,
Mathura Road, New Delhi -110044
Email: vinodgoel@panaceabiotec.com
Phone: D.I.D. +91-11-4167 9015
Fax: +91-11-4167 9070

Panacea Biotec Ltd.

CIN: L33117PB1984PLC022350

Registered Office: Ambala-Chandigarh Highway, Lalru - 140 501, Punjab, India. Ph.: +91-1762-505900, Fax: +91-1762-505906.
e-mail: corporate@panaceabiotec.com website: www.panaceabiotec.com

July 4, 2023

REF: SFSPL/QTR/June/2023

COMPANY SECRETARY
PANACEA BIOTEC LIMITED
B-1 EXTN A-27 MOHAN CO-
OPERATIVE INDUSTRIAL ESTAT
MATHURA ROAD BADARPUR NEW
DELHI 110044

Sub: Statement of Investor Complaints as per Regulation 13(3) of (LODR), 2015

Dear Sir/Madam,

This is to inform you that our Company **PANACEA BIOTEC LIMITED** having CIN: **L33117PB1984PLC022350** is registered on the SCORES platform of the SEBI in order to handle investor's complaints electronically.

As required under regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, this is the list of complaints received from complainants, complaints resolved as pending for consideration.

Number of investors complaints pending at the beginning of the quarter starting from 1st April, 2023	Complaints received during the Quarter From 1st April, 2023 To 30th June, 2023	Complaints disposed of during the Quarter From 1st April, 2023 To 30th June, 2023	Complaints remaining unresolved at the end of Quarter Ended on 30th June, 2023
NIL	NIL	NIL	NIL


Please find the details hereunder :-

S.No.	Received From	Pending at the end of last quarter	Received During the Quarter	Resolved	Total Pending
1	Directly from Investors	NIL	NIL	NIL	NIL
2	SEBI SCORES	NIL	NIL	NIL	NIL
3	Stock Exchanges	NIL	NIL	NIL	NIL
4	Other Sources (if Any)	NIL	NIL	NIL	NIL
5	Grand Total	NIL	NIL	NIL	NIL

We hereby certify that we have NIL pending complaints at our end for the period.

Thanking you,

For Skyline Financial Services Pvt. Limited


Vijay Kumar
(Authorised Signatory)
Investor Grievances Cell

FOR IDENTIFICATION
PURPOSES ONLY


Panacea Biotech Ltd
New Delhi-110044